<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721002</url>
  </required_header>
  <id_info>
    <org_study_id>H20-126</org_study_id>
    <nct_id>NCT04721002</nct_id>
  </id_info>
  <brief_title>Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)</brief_title>
  <acronym>MEDICI</acronym>
  <official_title>MEDICI - t(11;14) and BCL2 Expression in Patients With Multiple Myeloma: Prevalence, Stability Across Lines of Therapy and Concordance Across Sample Types</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood&#xD;
      cells). Most trial participants with MM relapse (cancer has come back) or become non-&#xD;
      responsive to treatment and remission gets shorter after each line of treatment. This is a&#xD;
      study to assess t(11;14) and BCL2 expression in adult participants with newly diagnosed and&#xD;
      relapsed/refractory (R/R) MM.&#xD;
&#xD;
      Approximately 500 adult participants with newly confirmed or relapsed/refractory (R/R)&#xD;
      multiple myeloma (MM) will be enrolled in around 15-20 countries.&#xD;
&#xD;
      Participants will receive standard of care while participating in this study. No drug will be&#xD;
      administered as a part of this study.&#xD;
&#xD;
      Participants will attend regular visits during the course of the study at a hospital or&#xD;
      clinic and will be asked to provide bone marrow and blood samples.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With t(11;14) Status by Fluorescence In Situ Hybridization (FISH) Analysis of Bone Marrow Plasma Cells</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>t(11;14) status (positive or negative) of the earliest multiple myeloma (MM) sample collected at initial diagnosis or across lines of therapies, by FISH analysis of bone marrow plasma cells is evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With BCL2 Status by Quantitative Polymerase Chain Reaction (qPCR) Analysis of Bone Marrow Plasma Cells</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>BCL2 status (BCL2 high or not) of the earliest MM sample collected, either at initial diagnosis or across lines of therapies, by qPCR analysis of bone marrow plasma cells is evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Stability of t(11;14) Status</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>Stability of t(11;14) status across intra-patient longitudinal bone marrow (BM) samples (changed vs not changed) collected at initial diagnosis and across lines of therapies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Stability of BCL2 Status</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>Stability of BCL2 status across intra-patient longitudinal BM samples (changed vs not changed) collected at initial diagnosis and across lines of therapies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With t(11;14) Status Determined by Bone Marrow (BM) Biopsy</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>t(11;14) status (positive or negative) at initial diagnosis and across lines of therapy as determined by BM biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With BCL2 Status Determined by Bone Marrow Biopsy</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>BCL2 status (BCL2high or BCL2low) at initial diagnosis and across lines of therapy as determined by BM biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With t(11;14) Status of MM Samples</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>t(11;14) status (positive or negative) of MM samples at different disease stages as determined by BM biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With BCL2 Status of MM Samples</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>BCL2 status (BCL2high or BCL2low) of MM samples at different disease stages as determined by BM biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With t(11;14) Status of MM Samples at Different Treatment Lines Stages</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>t(11;14) status (positive or negative) of MM samples at different treatment lines stages as determined by BM biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With BCL2 Status of MM Samples at Different Treatment Lines Stages</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>BCL2 status (BCL2high or BCL2low) status of MM samples at different treatment lines stages as determined by BM biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With t(1;14) Status and BCL2 Status</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>t(11;14) and BCL2 status (Positive and BCL2high, Negative and BCL2high, Positive and BCL2low, Negative and BCL2low) of the earliest MM samples collected, at initial diagnosis or across lines of therapies, by FISH and qPCR analyses of bone marrow plasma cells, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With FISH Fusion (F) Categories as Determined by BM Biopsy</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>FISH fusion (F) categories (1F, 2F, &gt;=3F) among t(11;14) positive samples as determined by BM biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With FISH Fusion (F) Categories Across Lines of Therapies as Determined by BM Biopsy</measure>
    <time_frame>Up to approximately 2.5 months following last subject last visit</time_frame>
    <description>FISH fusion (F) categories (1F, 2F, &gt;=3F) among t(11;14) positive samples across lines of therapies as determined by BM biopsy.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Multiple Myeloma (MM)</condition>
  <arm_group>
    <arm_group_label>Participants With Multiple Myeloma</arm_group_label>
    <description>Participants with newly diagnosed and relapsed/refractory multiple myeloma will receive standard of care. Bone marrow and blood samples will be collected.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bone marrow aspirate and peripheral blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants with confirmed newly diagnosed or relapsed/refractory multiple myeloma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed newly diagnosed or relapsed/refractory (R/R) Multiple myeloma (MM) who have&#xD;
             signed informed consent for the use of their biological material for research&#xD;
             purposes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who do not have Bone Marrow (BM) and blood sample at time of diagnosis or&#xD;
             at confirmation of relapse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tulane School of Medicine /ID# 223864</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center /ID# 223865</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-7208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires /ID# 224153</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <state>Ciuadad Autonoma De Buenos Aires</state>
        <zip>1199</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfred Health /ID# 224386</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital São Rafael /ID# 224307</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41253-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre /ID# 224274</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Sao Germano /ID# 224239</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>04537-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein/Farmacia da Oncologia /ID# 224303</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05652-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto COI de Educacao e Pesquisa /ID# 224245</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beneficencia Portuguesa de Sao Paulo /ID# 224305</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01323-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo /ID# 225749</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute /ID# 224172</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Zagreb /ID# 226969</name>
      <address>
        <city>Zagreb</city>
        <state>Grad Zagreb</state>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove /ID# 224089</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava /ID# 224090</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Dijon /ID# 223703</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d Or</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hopital Claude Huriez /ID# 228919</name>
      <address>
        <city>Lille</city>
        <state>Hauts-de-France</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Hotel Dieu -HME /ID# 223702</name>
      <address>
        <city>Nantes</city>
        <state>Pays-de-la-Loire</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hopital Necker /ID# 228062</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis am Volkspark /ID# 224763</name>
      <address>
        <city>Berlin</city>
        <zip>10715</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona /ID# 224761</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alexandra General Hospital /ID# 224828</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital /ID# 225514</name>
      <address>
        <city>Beaumont</city>
        <state>Dublin</state>
        <zip>D09 XR63</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center /ID# 224883</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <state>Tel-Aviv</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center-Hebrew University /ID# 224884</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 224690</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda /ID# 224608</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum /ID# 224694</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet OUS HF /ID# 227288</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii /ID# 227039</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Mar /ID# 227038</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institutul Clinic Fundeni /ID# 224574</name>
      <address>
        <city>Sector 2</city>
        <state>Bucuresti</state>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Noorah Oncology Center /ID# 224968</name>
      <address>
        <city>Jeddah</city>
        <zip>22384</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Medical Ctr Ljubljana /ID# 225408</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol /ID# 229281</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 224804</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Leon /ID# 229191</name>
      <address>
        <city>Leon</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz /ID# 229524</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre /ID# 225617</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca /ID# 224803</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital /ID# 227084</name>
      <address>
        <city>Taichung</city>
        <zip>407204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bagcilar Medipol Mega Universite Hastanesi /ID# 225515</name>
      <address>
        <city>Istanbul</city>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Saudi Arabia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma (MM)</keyword>
  <keyword>Relapsed/Refractory (R/R) Multiple myeloma (MM)</keyword>
  <keyword>t(11</keyword>
  <keyword>14)</keyword>
  <keyword>BCL2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

